NCT02501330Completed
Safety And Efficacy Of Bosutinib
DRUG USE INVESTIGATION OF BOSUTINIB FOR CML (POST MARKETING COMMITMENT PLAN)
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
The objective of this surveillance is to collect information about 1. adverse drug reaction not expected from the LPD (unknown adverse drug reaction) 2. the incidence of adverse drug reactions in this surveillance 3. factors considered to affect the safety and/or efficacy of this drug.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 702 (actual)
- First submitted
- 15 Jul 2015
- Start date
- 1 Jul 2015
- Primary completion date
- 28 Feb 2024
- Lead sponsor
- Pfizer
- NCT number
- NCT02501330
What you commit to
- Study type: Observational
- Participants enrolled: 702
- From 1 Jul 2015 to the primary completion date, 28 Feb 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of hypersensitivity
Other
- Women who may possibly be pregnant or become pregnant
Who the study is looking for
- Chronic myelogenous leukemia patients resistant or intolerant to prior treatment there is no experience with this drug
- Newly-diagnosed chronic phase Chronic myelogenous leukemia patients there is no experience with this drug
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.